» Articles » PMID: 35883682

Cyclic Hypoxia Induces Transcriptomic Changes in Mast Cells Leading to a Hyperresponsive Phenotype After FcεRI Cross-Linking

Overview
Journal Cells
Publisher MDPI
Date 2022 Jul 27
PMID 35883682
Authors
Affiliations
Soon will be listed here.
Abstract

Mast cells (MCs) play important roles in tumor development, executing pro- or antitumoral functions depending on tumor type and tumor microenvironment (TME) conditions. Cyclic hypoxia (cyH) is a common feature of TME since tumor blood vessels fail to provide a continuous supply of oxygen to the tumor mass. Here, we hypothesized that the localization of MCs in cyH regions within solid tumors could modify their transcriptional profile and activation parameters. Using confocal microscopy, we found an important number of MCs in cyH zones of murine melanoma B16-F1 tumors. Applying microarray analysis to examine the transcriptome of murine bone-marrow-derived MCs (BMMCs) exposed to interleaved cycles of hypoxia and re-oxygenation, we identified altered expression of 2512 genes. Functional enrichment analysis revealed that the transcriptional signature of MCs exposed to cyH is associated with oxidative phosphorylation and the FcεRI signaling pathway. Interestingly, FcεRI-dependent degranulation, calcium mobilization, and PLC-γ activity, as well as , , and gene expression after IgE/antigen challenge were increased in BMMCs exposed to cyH compared with those maintained in normoxia. Taken together, our findings indicate that cyH causes an important phenotypic change in MCs that should be considered in the design of inflammation-targeted therapies to control tumor growth.

Citing Articles

Chloride channels and mast cell function: pioneering new frontiers in IBD therapy.

Aljameeli A, Alsuwayt B, Bharati D, Gohri V, Mohite P, Singh S Mol Cell Biochem. 2025; .

PMID: 40038149 DOI: 10.1007/s11010-025-05243-w.


Mast cell-mediated microRNA functioning in immune regulation and disease pathophysiology.

Deng Q, Yao X, Fang S, Sun Y, Liu L, Li C Clin Exp Med. 2025; 25(1):38.

PMID: 39812911 PMC: 11735496. DOI: 10.1007/s10238-024-01554-2.


Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma.

Mao W, Xu K, Wang K, Zhang H, Ji J, Geng J iScience. 2024; 27(10):110921.

PMID: 39386756 PMC: 11462044. DOI: 10.1016/j.isci.2024.110921.


Identification of the mitophagy-related diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model.

Tu D, Cao J, Zhou J, Su B, Wang S, Jiang G Front Oncol. 2023; 13:1132559.

PMID: 36937391 PMC: 10014545. DOI: 10.3389/fonc.2023.1132559.


Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.

Zhu Y, Zheng J, Jia Q, Duan Z, Yao H, Yang J Cell Oncol (Dordr). 2022; 46(1):17-48.

PMID: 36367669 DOI: 10.1007/s13402-022-00741-1.

References
1.
Gonzalez-Espinosa C, Odom S, Olivera A, Hobson J, Martinez M, Oliveira-Dos-Santos A . Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med. 2003; 197(11):1453-65. PMC: 2193904. DOI: 10.1084/jem.20021806. View

2.
Snezhkina A, Kudryavtseva A, Kardymon O, Savvateeva M, Melnikova N, Krasnov G . ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells. Oxid Med Cell Longev. 2019; 2019:6175804. PMC: 6701375. DOI: 10.1155/2019/6175804. View

3.
Schluter A, Weller P, Kanaan O, Nel I, Heusgen L, Hoing B . CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma. BMC Cancer. 2018; 18(1):272. PMC: 5845191. DOI: 10.1186/s12885-018-4180-5. View

4.
Imbratta C, Hussein H, Andris F, Verdeil G . c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes. Front Immunol. 2020; 11:206. PMC: 7033575. DOI: 10.3389/fimmu.2020.00206. View

5.
Saitoh S, Arudchandran R, Manetz T, Zhang W, Sommers C, Love P . LAT is essential for Fc(epsilon)RI-mediated mast cell activation. Immunity. 2000; 12(5):525-35. DOI: 10.1016/s1074-7613(00)80204-6. View